USA flag logo/image

An Official Website of the United States Government

TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
N43CA130018
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
TERAPIO
11412 Bee Cave Rd Suite 100 AUSTIN, TX 78738-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: TOPIC 323 PHASE I; DEVELOPMENT OF RADIATION MODULATORS FOR USE DURING RADIOTHERAP
Agency: HHS
Contract: N43CA130018
Award Amount: $250,000.00
 

Abstract:

Oral mucositis (OM) is a common side effect in oncology patients receiving radiation treatment. Mucosal breakdown causes pain which leads to increased use of narcotic analgesics and restriction of food intake. OM often progresses to septicemia, increasinghospital stays and costs, and ultimately discontinuation of radiotherapy. This impacts overall effectiveness of cancer therapy so development of an agent for prevention and treatment of OM is clearly an unmet need. Terapio is developing a drug, RLIP76-Proteoliposome (RLIP76-PL), as a radiation countermeasure. When administered systemically, RLIP76-PL dramatically improves survival in a mouse model of whole body radiation, leading to the hypothesis that it could be beneficial as a local application in treating specific radiation toxicities such as OM. This proposed research will test that hypothesis. In Specific Aim #1, the current formulation of RLIP76-PL will be modified to be used as a topical mouthwash. In Aim #2, the efficacy of the topical formulation of RLIP76-PL will be tested in a hamster model to evaluate its effectiveness in reducing the severity of OM after irradiation. Finally, in Specific Aim #3, systemic absorption of mucosally-applied RLIP76-PL will be investigated to guide future studies in atumor model to establish that RLIP76-PL is not tumor-protective. PUBLIC HEALTH RELEVANCE

Principal Investigator:

Charles Cunningham
512-697-8179
CCUNNINGHAM@TERAPIO.COM

Business Contact:

Charles Cunningham
512-697-8179
CCUNNINGHAM@TERAPIO.COM
Small Business Information at Submission:

TERAPIO
11412 Bee Cave Rd Suite 100 AUSTIN, TX 78738-

EIN/Tax ID: 126388978
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No